Piloting 'mPal,' a Multilevel Strategy for Palliative Care Implementation
The purpose of this study is to assess the feasibility and acceptability of mPal, a multilevel implementation strategy to improve palliative care use among advanced stage lung cancer patients receiving cancer treatment.
Checked against the public recordLast updated May 13, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Laurie McLouth
- Interventions being studied
- Behavioral: mPal
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * new or recurrent AJCC stage IIIb-IV non-small cell lung cancer or extensive stage small cell lung cancer * ECOG performance status 0-3/Karnofsky 40-100 * at least three weeks into active oncologic treatment (chemotherapy, immunotherapy, chemo-immunotherapy) Exclusion Criteria: * unstable brain metastases * Cognitive (i.e., dementia) or psychiatric condition (e.g., psychotic disorder) for which participating would be inappropriate * Receiving palliative care * Unable to speak and read English
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of KentuckyLexington, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 13, 2025. Always confirm current availability with the study team.